When men are diagnosed with prostate cancer, the first question is usually what the next step will be. Unfortunately, this question usually doesn’t have an immediate answer, and the lack of an answer can be stressful. However, the time that elapses between diagnosis and the start of treatment is used for a very important process that involves many steps.

Key Takeaways

  • Treatment decisions in prostate cancer are never made on a single piece of information. They draw on tumour biology, disease extent, patient health, and personal priorities together.
  • Risk stratification based on PSA level, Gleason score, and staging is the clinical foundation on which all treatment decisions rest.
  • Multidisciplinary team review ensures that surgery, radiation, hormonal therapy, and systemic agents are all considered before a recommendation is made.
  • Patient preferences, including concerns about specific side effects and quality-of-life priorities, are a legitimate and important part of the final decision.

Why Prostate Cancer Decisions Are Particularly Nuanced

Prostate cancer is amongst the few cancers where the range of appropriate responses to the same diagnosis can legitimately include doing nothing right away or proceeding with aggressive surgery and hormonal treatment. This range exists because this disease encompasses a wide spectrum of aggressiveness where tumours may pose no threat to a man throughout his life or swift-growing forms of cancer demanding immediate treatment.

The Foundation: Staging and Grading

Before any treatment discussion begins, two pieces of information are essential: how aggressive the cancer is, and how far it has spread.

Grading reflects the microscopic appearance of the cancer cells under a pathologist's assessment. The Gleason score assigns a grade to the two most prominent tumour patterns seen on biopsy, with scores ranging from 6 to 10. These are now grouped into Grade Groups 1 through 5 for clearer communication.

Staging determines whether the cancer is confined to the prostate, has grown into surrounding tissue, has spread to regional lymph nodes, or has reached distant sites including bone. MRI of the prostate characterises local extent. Bone scan and CT or PSMA PET imaging identify metastatic disease.

Risk Stratification: Putting It Together

To recommend treatment, oncologists and urologists apply recognised risk stratification methods to classify patients. Commonly used methods classify patients into four groups: low risk, medium risk, high risk, and very high risk. 

This classification is correlated with treatment options, with low-risk disease prompting a decision on whether to apply active surveillance, while intermediate-risk disease requires careful consideration of whether active surveillance is enough or whether treatment needs to be applied.

The Role of the Multidisciplinary Team

Treatment recommendations for prostate cancer patients after a multidisciplinary review involving a urologist, a radiation oncologist, a medical oncologist, a radiologist and a pathologist. The importance of multidisciplinary teams in ensuring that the treatment plan is not based on the preferences of a single speciality is highlighted by the fact that all possible options can be reviewed against the patient's complete medical background. 

Patient-Specific Factors That Shape the Final Decision

Even when the tumour biology is clear, the treatment plan must also account for the individual in front of the clinician. Relevant patient factors include:

  • Age and life expectancy, which determine how much long-term risk reduction matters relative to short-term treatment burden
  • Overall fitness and comorbidities, particularly cardiovascular and kidney health, which influence which treatments can be safely tolerated
  • Baseline urinary, bowel, and sexual function, since the impact of surgery and radiation on these differs and matters considerably to quality of life
  • Preferences regarding the type and timing of side effects, as some patients prioritise avoiding surgical risks while others prefer to avoid the prolonged schedule of radiation

Molecular and Genetic Testing in Decision-Making

Genomic tests are also useful in providing prognostic information; for example, Oncotype DX Genomic Prostate Score or Decipher tests allow for gaining information that is beyond the standard pathological assessment of the tumour stage, which can be very helpful especially in the cases of intermediate-risk patients when it is not easy to make a choice between treatment and surveillance. Germline testing for BRCA1, BRCA2 and other genes controlling DNA repair was recommended for patients showing signs of high-risk or metastatic prostate cancer as well, considering that this genetic factor plays an important role in the patient's prognosis and accuracy of cancer treatment. 

When Hormonal and Targeted Therapy Enter the Plan

In the case of patients who are either locally advanced or have metastatic disease, androgen deprivation therapy is the standard practice. In the event of a castration-resistant case, meaning that the disease persists despite reduced testosterone levels, the natural step forward would be to implement newer hormone therapies which are more effective in inhibiting androgen signalling. 

The main agent in this respect is abiraterone acetate, which belongs to the group of CYP17A1 inhibitors and acts on the process of androgen synthesis. In this context, it is worth noting the fact that abiraterone operates at three different points; that is, it inhibits androgen production in the testes, in the adrenal glands, and within the tumour. 

Zybiraa 250mg is a formulation of abiraterone acetate co-administered with low-dose prednisolone to manage mineralocorticoid-related side effects. It is taken orally once daily on an empty stomach and requires monitoring of blood pressure, potassium, and liver function throughout treatment.

Managing Side Effects During Treatment

Side effects of treatment can differ greatly between various treatment methods and must be carefully considered before making any decision. For example, androgen deprivation therapy has the side effects of hot flashes, tiredness, low libido, loss of bone density, and elevated risk of cardiovascular issues with long-term use. Surgery poses a danger of urinary incontinence and impotence. Radiation therapy can cause urinary and bowel side effects that arise gradually.

Shared Decision-Making and Patient Involvement

Making the right treatment decision requires the patient to be fully aware of their choices so they can participate in the decision-making process. For instance, a patient may understand that maintaining sexual function is crucial to him or her or that having daily radiation therapy may not be an option because of work requirements. This information should help the medical team formulate a treatment plan the patient can actually follow. 

Importance of Follow-Up Care

PSA monitoring allows for timely intervention when any symptoms appear, especially when there is a recurrence of disease. Bone density and cardiovascular health monitoring are mandatory for long-term hormone therapy. Patients should also report any new symptoms to their medical team immediately.

What Is Worth Remembering

Doctors do not decide prostate cancer treatment on a single number or a single scan. They weigh tumour grade, disease extent, patient health, personal circumstances, and available evidence together before arriving at a recommendation. A patient who understands the factors that feed into that process is better positioned to ask the right questions, contribute their own priorities, and ultimately commit to the plan with confidence rather than uncertainty.

Disclaimer: This article is for general informational purposes only and should not be considered medical advice. Always consult a qualified urologist or oncologist for diagnosis, treatment planning, and guidance specific to your condition.